MEP20408A - Pharmaceutical dronedarone composition for parenteral administration - Google Patents

Pharmaceutical dronedarone composition for parenteral administration

Info

Publication number: MEP20408A
Authority: ME; Montenegro
Prior art keywords: pharmaceutical; parenteral administration; dronedarone; composition; dronedarone composition
Prior art date: 2000-12-11

Application number

MEP-204/08A

Other languages

Bosnian (bs)

English (en)

Croatian (hr)

Inventor

Sanofi-Synthelabo

Frederique Bourriague-Seve

Thierry Breul

Original Assignee

Sanofi Synthelabo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-11

Filing date

2001-12-10

Publication date

2010-06-10

2001-12-10 Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo

2010-06-10 Publication of MEP20408A publication Critical patent/MEP20408A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Oil, Petroleum & Natural Gas (AREA)
Cardiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

MEP-204/08A 2000-12-11 2001-12-10 Pharmaceutical dronedarone composition for parenteral administration MEP20408A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0016071A FR2817750B1 (fr)	2000-12-11	2000-12-11	Composition pharmaceutique de dronedarone pour administration parenterale
PCT/FR2001/003903 WO2002047660A1 (fr)	2000-12-11	2001-12-10	Composition pharmaceutique de dronedarone pour administration parenterale

Publications (1)

Publication Number	Publication Date
MEP20408A true MEP20408A (en)	2010-06-10

Family

ID=8857483

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MEP-204/08A MEP20408A (en)	2000-12-11	2001-12-10	Pharmaceutical dronedarone composition for parenteral administration
MEP-2008-204A ME00083B (me)	2000-12-11	2001-12-10	Farmaceutski oblik dronedarona za parenteralnu upotrebu

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MEP-2008-204A ME00083B (me)	2000-12-11	2001-12-10	Farmaceutski oblik dronedarona za parenteralnu upotrebu

Country Status (31)

Country	Link
US (1)	US6939865B2 (zh)
EP (1)	EP1343473B1 (zh)
JP (1)	JP4399161B2 (zh)
KR (1)	KR100849758B1 (zh)
CN (1)	CN1235566C (zh)
AR (1)	AR031649A1 (zh)
AT (1)	ATE348599T1 (zh)
AU (2)	AU1722902A (zh)
BG (1)	BG66187B1 (zh)
BR (1)	BR0116060B1 (zh)
CA (1)	CA2427375C (zh)
CZ (1)	CZ297788B6 (zh)
DE (1)	DE60125411T2 (zh)
EA (1)	EA005314B1 (zh)
FR (1)	FR2817750B1 (zh)
HK (1)	HK1055906A1 (zh)
HU (1)	HU229372B1 (zh)
IL (2)	IL155428A0 (zh)
IS (1)	IS2349B (zh)
MA (1)	MA26969A1 (zh)
ME (2)	MEP20408A (zh)
MX (1)	MXPA03005221A (zh)
NO (1)	NO332294B1 (zh)
NZ (1)	NZ525661A (zh)
OA (1)	OA12416A (zh)
PL (1)	PL199846B1 (zh)
RS (1)	RS50348B (zh)
SK (1)	SK287115B6 (zh)
TW (1)	TWI246926B (zh)
WO (1)	WO2002047660A1 (zh)
ZA (1)	ZA200303406B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009526851A (ja) *	2006-02-14	2009-07-23	ワイス	ＥＲβ選択的リガンドの水性薬学的配合物
GB0719180D0 (en)	2007-10-02	2007-11-14	Cambrex Karlskoga Ab	New process
AU2009252897B2 (en) *	2008-04-17	2015-03-19	Sanofi-Aventis	Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
FR2930149B1 (fr) *	2008-04-17	2011-02-18	Sanofi Aventis	Association de dronedarone avec au moins un diuretique, son application en therapeutique
EP2116239A1 (en) *	2008-04-29	2009-11-11	Sanofi-Aventis	Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
FR2959132A1 (fr) *	2010-04-22	2011-10-28	Sanofi Aventis	Procedes pour l'evaluation et la reduction des risques
TWI508726B (zh)	2009-12-21	2015-11-21	Gilead Sciences Inc	治療心房纖維性顫動之方法
US20120005128A1 (en) *	2010-06-29	2012-01-05	Sanofi	Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
US8602215B2 (en)	2010-06-30	2013-12-10	Sanofi	Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
CN102342907A (zh)	2010-07-30	2012-02-08	江苏恒瑞医药股份有限公司	决奈达隆固体分散体及其制备方法
KR20120094557A (ko) *	2011-02-01	2012-08-27	동아제약주식회사	피에이치 비의존적 용출양상을 갖는 부정맥치료제 제제
CN102908307A (zh) *	2011-08-03	2013-02-06	天津市嵩锐医药科技有限公司	供注射用盐酸决奈达隆药物组合物及其制备方法
EP2872119A1 (en) *	2012-07-12	2015-05-20	Sanofi	Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea
WO2022083636A1 (zh) *	2020-10-20	2022-04-28	上海博志研新药物技术有限公司	盐酸决奈达隆药物组合物、其制备方法及应用
WO2023019993A1 (zh) *	2021-08-16	2023-02-23	上海博志研新药物技术有限公司	盐酸决奈达隆注射组合物、其制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4727064A (en) *	1984-04-25	1988-02-23	The United States Of America As Represented By The Department Of Health And Human Services	Pharmaceutical preparations containing cyclodextrin derivatives
FR2746013B1 (fr) *	1996-03-18	1998-05-29	Sanofi Sa	Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
JP2004327321A (ja) *	2003-04-25	2004-11-18	Jst Mfg Co Ltd	コネクタ

2000
- 2000-12-11 FR FR0016071A patent/FR2817750B1/fr not_active Expired - Fee Related
2001
- 2001-12-10 WO PCT/FR2001/003903 patent/WO2002047660A1/fr active IP Right Grant
- 2001-12-10 JP JP2002549234A patent/JP4399161B2/ja not_active Expired - Fee Related
- 2001-12-10 SK SK726-2003A patent/SK287115B6/sk not_active IP Right Cessation
- 2001-12-10 EP EP01270322A patent/EP1343473B1/fr not_active Expired - Lifetime
- 2001-12-10 AR ARP010105716A patent/AR031649A1/es not_active Application Discontinuation
- 2001-12-10 RS YUP-465/03A patent/RS50348B/sr unknown
- 2001-12-10 MX MXPA03005221A patent/MXPA03005221A/es active IP Right Grant
- 2001-12-10 CZ CZ20031612A patent/CZ297788B6/cs not_active IP Right Cessation
- 2001-12-10 CA CA2427375A patent/CA2427375C/fr not_active Expired - Fee Related
- 2001-12-10 CN CNB018203884A patent/CN1235566C/zh not_active Expired - Fee Related
- 2001-12-10 DE DE60125411T patent/DE60125411T2/de not_active Expired - Lifetime
- 2001-12-10 ME MEP-204/08A patent/MEP20408A/xx unknown
- 2001-12-10 AT AT01270322T patent/ATE348599T1/de not_active IP Right Cessation
- 2001-12-10 PL PL362788A patent/PL199846B1/pl unknown
- 2001-12-10 TW TW090130522A patent/TWI246926B/zh not_active IP Right Cessation
- 2001-12-10 ZA ZA200303406A patent/ZA200303406B/en unknown
- 2001-12-10 US US10/450,320 patent/US6939865B2/en not_active Expired - Lifetime
- 2001-12-10 ME MEP-2008-204A patent/ME00083B/me unknown
- 2001-12-10 NZ NZ525661A patent/NZ525661A/en not_active IP Right Cessation
- 2001-12-10 AU AU1722902A patent/AU1722902A/xx active Pending
- 2001-12-10 IL IL15542801A patent/IL155428A0/xx active IP Right Grant
- 2001-12-10 EA EA200300406A patent/EA005314B1/ru not_active IP Right Cessation
- 2001-12-10 HU HU0500842A patent/HU229372B1/hu not_active IP Right Cessation
- 2001-12-10 AU AU2002217229A patent/AU2002217229B2/en not_active Ceased
- 2001-12-10 BR BRPI0116060-5B1A patent/BR0116060B1/pt not_active IP Right Cessation
- 2001-12-10 OA OA1200300152A patent/OA12416A/fr unknown
- 2001-12-10 KR KR1020037007744A patent/KR100849758B1/ko active IP Right Grant
2003
- 2003-04-14 IL IL155428A patent/IL155428A/en not_active IP Right Cessation
- 2003-04-18 BG BG107748A patent/BG66187B1/bg unknown
- 2003-04-29 NO NO20031958A patent/NO332294B1/no not_active IP Right Cessation
- 2003-04-30 IS IS6801A patent/IS2349B/is unknown
- 2003-06-03 MA MA27190A patent/MA26969A1/fr unknown
- 2003-11-14 HK HK03108327A patent/HK1055906A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
IS2349B (is)	2008-04-15
OA12416A (fr)	2006-04-18
EP1343473A1 (fr)	2003-09-17
CZ297788B6 (cs)	2007-03-28
FR2817750A1 (fr)	2002-06-14
BG107748A (bg)	2004-03-31
MA26969A1 (fr)	2004-12-20
BR0116060B1 (pt)	2013-12-31
HUP0500842A2 (hu)	2005-12-28
ATE348599T1 (de)	2007-01-15
CA2427375C (fr)	2011-02-01
JP2004528277A (ja)	2004-09-16
IL155428A0 (en)	2003-11-23
HU229372B1 (en)	2013-11-28
SK287115B6 (sk)	2009-12-07
YU46503A (sh)	2006-08-17
NO20031958L (no)	2003-06-11
CZ20031612A3 (cs)	2003-09-17
TWI246926B (en)	2006-01-11
HK1055906A1 (en)	2004-01-30
AR031649A1 (es)	2003-09-24
IL155428A (en)	2007-10-31
BG66187B1 (bg)	2011-12-30
US20040044070A1 (en)	2004-03-04
RS50348B (sr)	2009-11-10
EP1343473B1 (fr)	2006-12-20
EA005314B1 (ru)	2004-12-30
EA200300406A1 (ru)	2003-10-30
US6939865B2 (en)	2005-09-06
MXPA03005221A (es)	2004-03-26
IS6801A (is)	2003-04-30
NO20031958D0 (no)	2003-04-29
CN1235566C (zh)	2006-01-11
NZ525661A (en)	2004-11-26
FR2817750B1 (fr)	2003-02-21
CN1479610A (zh)	2004-03-03
PL362788A1 (en)	2004-11-02
WO2002047660A1 (fr)	2002-06-20
SK7262003A3 (en)	2004-02-03
ZA200303406B (en)	2004-05-03
CA2427375A1 (fr)	2002-06-20
AU1722902A (en)	2002-06-24
DE60125411D1 (de)	2007-02-01
AU2002217229B2 (en)	2006-05-18
DE60125411T2 (de)	2007-10-11
KR100849758B1 (ko)	2008-07-31
ME00083B (me)	2010-10-10
NO332294B1 (no)	2012-08-20
PL199846B1 (pl)	2008-11-28
KR20030060985A (ko)	2003-07-16
BR0116060A (pt)	2004-03-02
JP4399161B2 (ja)	2010-01-13

Publication	Publication Date	Title
MEP20408A (en)	2010-06-10	Pharmaceutical dronedarone composition for parenteral administration
HRP20020880B1 (en)	2006-04-30	New pharmaceutical composition
MEP33708A (en)	2010-10-10	Pharmaceutical compositions comprising a hmg coa reductase inhibitor
EE05081B1 (et)	2008-10-15	Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
NO20025621D0 (no)	2002-11-22	Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
HUP0302086A2 (hu)	2003-12-29	Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
ME00180B (me)	2010-10-10	Kiseli preparati insulina sa poboljšanom stabilnošću
HRP20010243B1 (en)	2011-02-28	Compositions containing diphosphonic acids
CY1112139T1 (el)	2015-11-04	Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
ATE213940T1 (de)	2002-03-15	Parenteral anzuwendende arzneizubereitung enthaltend amiodaron
MY122124A (en)	2006-03-31	Solid pharmaceutical composition containing benzofurane derivatives
DK1766003T3 (da)	2008-12-08	Thrombinpræparater
DE69231663D1 (de)	2001-03-01	Konjugate bestehend aus polysaccharid und protein
CY1107819T1 (el)	2013-06-19	Φαρμακευτικη διαμορφωση της ολανζαπινης
DK1104289T3 (da)	2006-05-15	Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
RS50310B (sr)	2009-09-08	Farmaceutska kompozicija koja sadrži ciklesonid za primenu na sluzokoži
BR0317623A (pt)	2005-11-29	Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
DE69921486D1 (de)	2004-12-02	Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
ES2197781A1 (es)	2004-01-01	Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
FR2793685B1 (fr)	2001-08-24	Compositions pharmaceutiques, destinees a l'administration par voie orale de phloroglucinol et leur preparation
SE0001916D0 (sv)	2000-05-23	Novel formulation
HRP20010764B1 (en)	2011-01-31	Prucalopride oral solution
YU87501A (sh)	2004-05-12	Farmaceutski kompleksi
CL2011000439A1 (es)	2011-07-15	Formulacion farmaceutica que consiste esencialmente de 50 mg/ml de clorhidrato de canfosfamida en 100 mm de un amortiguador acuoso de citrato de sodio a ph 4,6; formulacion liofilizada que la comprende; y metodo de preparacion de la formulacion farmaceutica.
MXPA03004111A (es)	2004-05-05	Composiciones de n-(1 -metiletilaminocarbonil)-4 -(3-metilfenilamino) -3-piridil-sulfonamida y oligosacaridos ciclicos con una mayor liberacion.